GADOLIN: Rituximab-Refractory* Patients Who Progressed Early and Had 1-10 Prior Therapies 1

  • 95% ECOG PS of 0-1 
  • 5% ECOG PS of 2
  • Median age: 63 (range 34-87) 

The follicular lymphoma patients studied in this trial were refractory to rituximab product-containing regimens that primarily included R-CHOP, R-CVP, and rituximab product monotherapy 1,2 

Only 2 patients enrolled into the trial had prior bendamustine exposure.
R-CHOP, rituximab product, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone;
R-CVP, rituximab product, cyclophosphamide, vincristine sulfate, and prednisone.
*Rituximab-refractory was defined as patients who had no response to or who progressed within 6 months of therapy.